BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 29279943)

  • 21. Risk stratification of diffuse large B-cell lymphoma with interim PET-CT based on different cutoff Deauville scores.
    Kim J; Song YS; Lee JS; Lee WW; Kim SE
    Leuk Lymphoma; 2018 Feb; 59(2):340-347. PubMed ID: 28629257
    [TBL] [Abstract][Full Text] [Related]  

  • 22. FDG PET/CT Maximum Tumor Dissemination to Predict Recurrence in Patients with Diffuse Large B-Cell Lymphoma.
    Jo JH; Chung HW; Kim SY; Lee MH; So Y
    Nucl Med Mol Imaging; 2023 Feb; 57(1):26-33. PubMed ID: 36643943
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic value of negative interim 2-[¹⁸F]-fluoro-2-deoxy-d-glucose PET/CT in diffuse large B-cell lymphoma.
    Kwon SH; Kang DR; Kim J; Yoon JK; Lee SJ; Jeong SH; Lee HW; An YS
    Clin Radiol; 2016 Mar; 71(3):280-6. PubMed ID: 26732889
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 18F-FDG PET/CT qualitative and quantitative evaluation in neurofibromatosis type 1 patients for detection of malignant transformation: comparison of early to delayed imaging with and without liver activity normalization.
    Chirindel A; Chaudhry M; Blakeley JO; Wahl R
    J Nucl Med; 2015 Mar; 56(3):379-85. PubMed ID: 25655626
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Value of interim FDG PET/CT for predicting outcome of patients with angioimmunoblastic T-cell lymphoma.
    Moon SH; Lee AY; Kim WS; Kim SJ; Cho YS; Choe YS; Kim BT; Lee KH
    Leuk Lymphoma; 2017 Jun; 58(6):1341-1348. PubMed ID: 27718766
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In newly diagnosed diffuse large B-cell lymphoma, determination of bone marrow involvement with 18F-FDG PET/CT provides better diagnostic performance and prognostic stratification than does biopsy.
    Berthet L; Cochet A; Kanoun S; Berriolo-Riedinger A; Humbert O; Toubeau M; Dygai-Cochet I; Legouge C; Casasnovas O; Brunotte F
    J Nucl Med; 2013 Aug; 54(8):1244-50. PubMed ID: 23674577
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic Importance of Bone Marrow Uptake on Baseline
    Soydal C; Koksoy EB; Yasar A; Turgal E; Erdogan BD; Akbulut H; Kucuk NO
    Cancer Biother Radiopharm; 2016 Dec; 31(10):361-365. PubMed ID: 27996313
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 18F-FDG PET/CT for Prognostic Stratification of Patients With Extranodal Natural Killer/T-Cell Lymphoma.
    Qin C; Yang S; Sun X; Xia X; Li C; Lan X
    Clin Nucl Med; 2019 Mar; 44(3):201-208. PubMed ID: 30624268
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Use of FDG PET/CT in identification of bone marrow involvement in diffuse large B cell lymphoma and follicular lymphoma: comparison with iliac crest bone marrow biopsy.
    Teagle AR; Barton H; Charles-Edwards E; Dizdarevic S; Chevassut T
    Acta Radiol; 2017 Dec; 58(12):1476-1484. PubMed ID: 28382828
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Prognostic Value of Interim PET/CT in 227 Patients of DLBCL].
    Wang RM; Li F; Liu CB; Guan ZW; Fu LP; Xu BX; Zhu HY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Feb; 27(1):74-79. PubMed ID: 30738450
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fluorodeoxyglucose positron emission tomography (FDG-PET) and PET/computed tomography imaging characteristics of thyroid lymphoma and their potential clinical utility.
    Basu S; Li G; Bural G; Alavi A
    Acta Radiol; 2009 Mar; 50(2):201-4. PubMed ID: 19089692
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The prognostic role of end-of-treatment FDG-PET/CT in diffuse large B cell lymphoma: a pilot study application of neural networks to predict time-to-event.
    Annunziata S; Pelliccioni A; Hohaus S; Maiolo E; Cuccaro A; Giordano A
    Ann Nucl Med; 2021 Jan; 35(1):102-110. PubMed ID: 33094420
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of hepatic steatosis on liver FDG uptake measured in mean standard uptake values.
    Abele JT; Fung CI
    Radiology; 2010 Mar; 254(3):917-24. PubMed ID: 20177102
    [TBL] [Abstract][Full Text] [Related]  

  • 34. FDG-PET/CT at the end of immuno-chemotherapy in follicular lymphoma: the prognostic role of the ratio between target lesion and liver SUV
    Annunziata S; Cuccaro A; Tisi MC; Hohaus S; Rufini V
    Ann Nucl Med; 2018 Jun; 32(5):372-377. PubMed ID: 29464479
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Accumulation of (18)F-FDG in the liver in hepatic steatosis.
    Keramida G; Potts J; Bush J; Verma S; Dizdarevic S; Peters AM
    AJR Am J Roentgenol; 2014 Sep; 203(3):643-8. PubMed ID: 25148170
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combined modality treatment for PET-positive non-Hodgkin lymphoma: favorable outcomes of combined modality treatment for patients with non-Hodgkin lymphoma and positive interim or postchemotherapy FDG-PET.
    Halasz LM; Jacene HA; Catalano PJ; Van den Abbeele AD; Lacasce A; Mauch PM; Ng AK
    Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):e647-54. PubMed ID: 22607911
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Variability of Hepatic 18F-FDG Uptake at Interim PET in Patients With Hodgkin Lymphoma.
    Rubello D; Gordien P; Morliere C; Guyot M; Bordenave L; Colletti PM; Hindié E
    Clin Nucl Med; 2015 Aug; 40(8):e405-10. PubMed ID: 26018686
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostication of diffuse large B-cell lymphoma patients with Deauville score of 3 or 4 at end-of-treatment PET evaluation: a comparison of the Deauville 5-point scale and the ΔSUVmax method.
    Ng DZ; Lee CY; Lam WW; Tong AK; Tan SH; Khoo LP; Tan YH; Chiang J; Chang EW; Chan JY; Poon EY; Somasundaram N; Farid H Rashid M; Tao M; Lim ST; Yang VS
    Leuk Lymphoma; 2022 Jan; 63(1):256-259. PubMed ID: 34665693
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Correlation of 18-fluorodeoxyglucose PET/computed tomography parameters and clinical features to predict outcome for diffuse large B-cell lymphoma.
    Baratto L; Wu F; Minamimoto R; Hatami N; Liang T; Sabile J; Advani RH; Mittra E
    Nucl Med Commun; 2021 Jul; 42(7):792-799. PubMed ID: 33741852
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Utility of interim and end-of-treatment PET/CT in peripheral T-cell lymphomas: A review of 124 patients.
    El-Galaly TC; Pedersen MB; Hutchings M; Mylam KJ; Madsen J; Gang AO; Bøgsted M; de Nully Brown P; Loft A; Nielsen AL; Hendel HW; Iyer V; Gormsen LC
    Am J Hematol; 2015 Nov; 90(11):975-80. PubMed ID: 26201505
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.